@article{bravo_vergel_cost-effectiveness_2007-1,
	title = {The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis},
	volume = {46},
	issn = {1462-0324},
	url = {https://academic.oup.com/rheumatology/article/46/11/1729/1785952},
	doi = {10.1093/rheumatology/kem221},
	abstract = {Abstract. Objective. Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic},
	language = {en},
	number = {11},
	urldate = {2019-08-06},
	journal = {Rheumatology},
	author = {Bravo Vergel, Y. and Hawkins, N. S. and Claxton, K. and Asseburg, C. and Palmer, S. and Woolacott, N. and Bruce, I. N. and Sculpher, M. J.},
	month = nov,
	year = {2007},
	keywords = {Adult, Antibodies, Antirheumatic Agents, Arthritis, Bayes Theorem, Clinical Trials, Cost-Benefit Analysis, Drug Costs, Etanercept, Female, Humans, Immunoglobulin G, Infliximab, Male, Middle Aged, Monoclonal, Palliative Care, Phase III as Topic, Psoriatic, Receptors, State Medicine, Treatment Outcome, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha},
	pages = {1729--1735},
	file = {Full Text PDF:/Users/neil.hawkins/Zotero/storage/SVLD4TKB/Bravo Vergel et al. - 2007 - The cost-effectiveness of etanercept and inflixima.pdf:application/pdf;Snapshot:/Users/neil.hawkins/Zotero/storage/TQBAJK2T/1785952.html:text/html},
}

{"_id":"MmmjeqbNbeMRSQ2rQ","bibbaseid":"bravovergel-hawkins-claxton-asseburg-palmer-woolacott-bruce-sculpher-thecosteffectivenessofetanerceptandinfliximabforthetreatmentofpatientswithpsoriaticarthritis-2007","authorIDs":[],"author_short":["Bravo Vergel, Y.","Hawkins, N. S.","Claxton, K.","Asseburg, C.","Palmer, S.","Woolacott, N.","Bruce, I. N.","Sculpher, M. J."],"bibdata":{"bibtype":"article","type":"article","title":"The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis","volume":"46","issn":"1462-0324","url":"https://academic.oup.com/rheumatology/article/46/11/1729/1785952","doi":"10.1093/rheumatology/kem221","abstract":"Abstract. Objective. Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic","language":"en","number":"11","urldate":"2019-08-06","journal":"Rheumatology","author":[{"propositions":[],"lastnames":["Bravo","Vergel"],"firstnames":["Y."],"suffixes":[]},{"propositions":[],"lastnames":["Hawkins"],"firstnames":["N.","S."],"suffixes":[]},{"propositions":[],"lastnames":["Claxton"],"firstnames":["K."],"suffixes":[]},{"propositions":[],"lastnames":["Asseburg"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Palmer"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Woolacott"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Bruce"],"firstnames":["I.","N."],"suffixes":[]},{"propositions":[],"lastnames":["Sculpher"],"firstnames":["M.","J."],"suffixes":[]}],"month":"November","year":"2007","keywords":"Adult, Antibodies, Antirheumatic Agents, Arthritis, Bayes Theorem, Clinical Trials, Cost-Benefit Analysis, Drug Costs, Etanercept, Female, Humans, Immunoglobulin G, Infliximab, Male, Middle Aged, Monoclonal, Palliative Care, Phase III as Topic, Psoriatic, Receptors, State Medicine, Treatment Outcome, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha","pages":"1729–1735","file":"Full Text PDF:/Users/neil.hawkins/Zotero/storage/SVLD4TKB/Bravo Vergel et al. - 2007 - The cost-effectiveness of etanercept and inflixima.pdf:application/pdf;Snapshot:/Users/neil.hawkins/Zotero/storage/TQBAJK2T/1785952.html:text/html","bibtex":"@article{bravo_vergel_cost-effectiveness_2007-1,\n\ttitle = {The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis},\n\tvolume = {46},\n\tissn = {1462-0324},\n\turl = {https://academic.oup.com/rheumatology/article/46/11/1729/1785952},\n\tdoi = {10.1093/rheumatology/kem221},\n\tabstract = {Abstract. Objective. Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2019-08-06},\n\tjournal = {Rheumatology},\n\tauthor = {Bravo Vergel, Y. and Hawkins, N. S. and Claxton, K. and Asseburg, C. and Palmer, S. and Woolacott, N. and Bruce, I. N. and Sculpher, M. J.},\n\tmonth = nov,\n\tyear = {2007},\n\tkeywords = {Adult, Antibodies, Antirheumatic Agents, Arthritis, Bayes Theorem, Clinical Trials, Cost-Benefit Analysis, Drug Costs, Etanercept, Female, Humans, Immunoglobulin G, Infliximab, Male, Middle Aged, Monoclonal, Palliative Care, Phase III as Topic, Psoriatic, Receptors, State Medicine, Treatment Outcome, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha},\n\tpages = {1729--1735},\n\tfile = {Full Text PDF:/Users/neil.hawkins/Zotero/storage/SVLD4TKB/Bravo Vergel et al. - 2007 - The cost-effectiveness of etanercept and inflixima.pdf:application/pdf;Snapshot:/Users/neil.hawkins/Zotero/storage/TQBAJK2T/1785952.html:text/html},\n}\n\n","author_short":["Bravo Vergel, Y.","Hawkins, N. S.","Claxton, K.","Asseburg, C.","Palmer, S.","Woolacott, N.","Bruce, I. N.","Sculpher, M. J."],"bibbaseid":"bravovergel-hawkins-claxton-asseburg-palmer-woolacott-bruce-sculpher-thecosteffectivenessofetanerceptandinfliximabforthetreatmentofpatientswithpsoriaticarthritis-2007","role":"author","urls":{"Paper":"https://academic.oup.com/rheumatology/article/46/11/1729/1785952"},"keyword":["Adult","Antibodies","Antirheumatic Agents","Arthritis","Bayes Theorem","Clinical Trials","Cost-Benefit Analysis","Drug Costs","Etanercept","Female","Humans","Immunoglobulin G","Infliximab","Male","Middle Aged","Monoclonal","Palliative Care","Phase III as Topic","Psoriatic","Receptors","State Medicine","Treatment Outcome","Tumor Necrosis Factor","Tumor Necrosis Factor-alpha"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","creationDate":"2019-08-06T22:27:23.105Z","downloads":0,"keywords":["adult","antibodies","antirheumatic agents","arthritis","bayes theorem","clinical trials","cost-benefit analysis","drug costs","etanercept","female","humans","immunoglobulin g","infliximab","male","middle aged","monoclonal","palliative care","phase iii as topic","psoriatic","receptors","state medicine","treatment outcome","tumor necrosis factor","tumor necrosis factor-alpha"],"search_terms":["cost","effectiveness","etanercept","infliximab","treatment","patients","psoriatic","arthritis","bravo vergel","hawkins","claxton","asseburg","palmer","woolacott","bruce","sculpher"],"title":"The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis","year":2007,"dataSources":["usc9shidSEoJgjLwM","t2Yoxo7tWvphNtRzd","ZaHtWavQhcwZqKLNF","dKPQSqAsJNG2yGZjP","iRRNaRs6FkffgErta","gZzkdjqc3Tjd8fnQA","zeMwFvgpdRkYAkfoD","v8uQmZsBpiqycmskv"]}